Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05966584 · ClinicalTrials.gov registry record · Phase 2
A Study to Prevent Rash in People Starting Alpelisib for the Treatment of Breast Cancer
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT05966584: Clinical Trial Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT05966584 is a Phase 2 study that was terminated before completion, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 1 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05966584, a Phase 2 study, was terminated before completion, sponsored by Memorial Sloan Kettering Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
The researcher are doing this study to find out whether benralizumab is effective at preventing skin rashes caused by alpelisib in people who have metastatic breast cancer. Skin rash is a common side effect of alpelisib. Researchers think adding benralizumab to the standard-of-care hormone treatment and alpelisib may prevent the patient from getting a rash.
Interventions
- DRUG Benralizumab
- DRUG fulvestrant or AIs) and PI3K inhibition (alpelisib)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2023-07-06 |
| Est. Completion | 2024-08-02 |
| Phase | Phase 2 |
Why NCT05966584 stopped before completion
NCT05966584 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which Benralizumab is the first listed.
NCT05966584 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05966584 about?
NCT05966584 is a clinical study titled "A Study to Prevent Rash in People Starting Alpelisib for the Treatment of Breast Cancer". The researcher are doing this study to find out whether benralizumab is effective at preventing skin rashes caused by alpelisib in people who have metastatic breast cancer. Skin rash is a common side effect of alpelisib. Researchers think adding benralizumab to the standard-of-care hormone treatment...
What is the current status of trial NCT05966584?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2023-07-06. Estimated completion is 2024-08-02.
What interventions are being tested in trial NCT05966584?
The interventions under investigation include: Benralizumab (DRUG), fulvestrant or AIs) and PI3K inhibition (alpelisib) (DRUG).
Who is sponsoring clinical trial NCT05966584?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05966584's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI